000089651 001__ 89651
000089651 005__ 20230921135432.0
000089651 0247_ $$2doi$$a10.3390/vaccines8020206
000089651 0248_ $$2sideral$$a117755
000089651 037__ $$aART-2020-117755
000089651 041__ $$aeng
000089651 100__ $$aDe Pablo-Maiso, Lorena
000089651 245__ $$aSendai virus, a strong inducer of anti-lentiviral state in ovine cells
000089651 260__ $$c2020
000089651 5060_ $$aAccess copy available to the general public$$fUnrestricted
000089651 5203_ $$aSmall ruminant lentiviruses (SRLVs) are widely spread in the ovine and caprine populations, causing an incurable disease affecting animal health and production. Vaccine development is hindered owing to the high genetic heterogeneity of lentiviruses and the selection of T-cell and antibody escape mutants, requiring antigen delivery optimization. Sendai virus (SeV) is a respiratory paramyxovirus in mice that has been recognized as a potent inducer of innate immune responses in several species, including mouse and human. The aim of this study was to stimulate an innate antiviral response in ovine cells and evaluate the potential inhibitory effect upon small ruminant lentivirus (SRLV) infections. Ovine alveolar macrophages (AMs), blood-derived macrophages (BDMs), and skin fibroblasts (OSFs) were stimulated through infection with SeV encoding green fluorescent protein (GFP). SeV efficiently infected ovine cells, inducing an antiviral state in AM from SRLV naturally-infected animals, as well as in in vitro SRLV-infected BDM and OSF from non-infected animals. Supernatants from SeV-infected AM induced an antiviral state when transferred to fresh cells challenged with SRLV. Similar to SRLV, infectivity of an HIV-1-GFP lentiviral vector was also restricted in ovine cells infected with SeV. In myeloid cells, an M1-like proinflammatory polarization was observed together with an APOBEC3Z1 induction, among other lentiviral restriction factors. Our observations may boost new approximations in ameliorating the SRLV burden by stimulation of the innate immune response using SeV-based vaccine vectors.
000089651 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/RTI2018-096172-B-C31
000089651 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000089651 590__ $$a4.422$$b2020
000089651 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b63 / 140 = 0.45$$c2020$$dQ2$$eT2
000089651 591__ $$aIMMUNOLOGY$$b74 / 162 = 0.457$$c2020$$dQ2$$eT2
000089651 592__ $$a1.296$$b2020
000089651 593__ $$aDrug Discovery$$c2020$$dQ1
000089651 593__ $$aImmunology$$c2020$$dQ1
000089651 593__ $$aPharmacology (medical)$$c2020$$dQ1
000089651 593__ $$aPharmacology$$c2020$$dQ1
000089651 593__ $$aInfectious Diseases$$c2020$$dQ1
000089651 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000089651 700__ $$aEcheverría, Irache
000089651 700__ $$aRius-Rocabert, Sergio
000089651 700__ $$0(orcid)0000-0002-2053-9842$$aLuján, Lluis$$uUniversidad de Zaragoza
000089651 700__ $$aGarcin, Dominique
000089651 700__ $$aDe Andrés, Damián
000089651 700__ $$aNistal-Villán, Estanislao
000089651 700__ $$aReina, Ramsés
000089651 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000089651 773__ $$g8, 2 (2020), 206 [16 pp.]$$tVaccines$$x2076-393X
000089651 8564_ $$s1708056$$uhttps://zaguan.unizar.es/record/89651/files/texto_completo.pdf$$yVersión publicada
000089651 8564_ $$s486712$$uhttps://zaguan.unizar.es/record/89651/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000089651 909CO $$ooai:zaguan.unizar.es:89651$$particulos$$pdriver
000089651 951__ $$a2023-09-21-13:30:29
000089651 980__ $$aARTICLE